Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
about
Treatment options in non-muscle-invasive bladder cancer after BCG failureBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseBacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive DiseaseTreatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancerRadical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.The arguments for an early cystectomy in patients with urothelial carcinoma.Proactive approach to treat high-grade lamina-invasive bladder cancer.Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.Best practice in the treatment of nonmuscle invasive bladder cancer.Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.Survival up to 5-15 years in young women following genital sparing radical cystectomy and neobladder: oncological outcome and quality of life. Single-surgeon and single-institution experienceThe Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer.Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.The management of BCG failure in non-muscle-invasive bladder cancer: an update.Genomic characterization of high-risk non-muscle invasive bladder cancerLong-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy.High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.Is 'second-look' (re-staging) transurethral resection of bladder tumours a new standard of care?New developments in the management of nonmuscle invasive bladder cancer.Optimized management in patients with bladder cancer.Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer.Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and the presence of residual tumor tissue.Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis.Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort.Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.Re-examination of the natural history of high-grade T1 bladder cancer using a large contemporary cohort.Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
P2860
Q26775977-923F5C43-FC16-461E-B9FD-8B569494CADFQ27011829-FB924CF7-93BE-4C9F-A6C0-F770F599219DQ31112248-663CC8D9-FFDC-45E6-9ACB-9DA36B880133Q34758436-8050132E-A997-490B-8F3C-A86700FD4661Q35014729-124004D0-A726-4996-804A-E85ADBBEAFE0Q35028272-396F5FC6-0C2E-4FD1-AE62-05AEA38F129DQ35125741-B0AC9FC6-9FB7-4318-8BD9-41AC764FC716Q35677853-EB926BD3-DBAD-46B8-AF0F-C6E3F981FC1AQ35688392-8283391B-A42D-428B-84A7-9E950881FBDAQ35762587-5D766E7C-4E7C-4289-B4D9-DD7762D6A099Q35921521-A3394EC5-CCF8-4B18-A0B6-B340E735C9FAQ36208889-698F6001-5055-41EC-9230-61A93CEDCA46Q37053829-3D976276-DC46-4F6A-9D11-ECA45447253FQ37221184-D1E20D9C-1F9A-4757-9C23-B48BA6E52B5EQ37457728-F346160C-D09B-4BB8-A730-DCC6918E9FC6Q37472576-D700C91A-DF10-4039-BA71-81E4C81C7FACQ37688916-C7A55F32-287E-4686-B66D-E9B584DE9A77Q37813081-99BEAB85-3160-4A5C-BBD2-8A19B1D8FA60Q37872240-D357DDE6-6FC3-4C43-B5C9-8A583ACFA05CQ38052445-C44FC49B-9D2D-4F79-B628-696472973C67Q38636903-B203DEE2-23BE-4DCE-B0A9-2CAB1BE02EFBQ38914895-D35A6A64-F13E-43D5-859F-2F1D69F7B47AQ39921939-E57EC678-0F79-460E-9CF3-FFAAE6FC16E2Q40100639-ED25AAE2-884C-440B-8BCC-F3216BB84B5CQ42370597-3A348EEC-F3CB-4771-B965-68695BD0827BQ44312237-E1527FBD-4AB1-4220-B34A-B29D422D0F37Q44529718-B2180936-8FC9-44B1-91DE-B8D6EF4ED962Q44895726-3A12DEFF-582F-4C65-B5FA-CA76F94946B5Q46906313-DDC17900-0D96-4F6C-879A-D5680B0E24B6Q47105909-EF3A48F9-29A8-4134-B155-864F38E0EDFEQ47348716-AC80F316-4DBF-4102-B81B-1216E680CA30Q48288809-99955579-3344-48A9-AE93-6FFEA804A22EQ52632425-F4B3B6B8-F529-4EBA-97E8-26F22C027A30Q55517522-54BA1588-58BA-48C7-AC87-7E0CFB4D6062Q58463132-735C0276-7084-4254-A38C-E5D0DE7C08BE
P2860
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@ast
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@en
type
label
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@ast
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@en
prefLabel
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@ast
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@en
P2093
P50
P1476
Treatment paradigm shift may i ...... sk superficial bladder cancer.
@en
P2093
Angel M Serio
Ganesh V Raj
Harry Herr
P304
1283-6; discussion 1286
P356
10.1016/J.JURO.2006.11.090
P407
P577
2007-04-01T00:00:00Z